Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1119.2000 -9.70 (-0.86%)
NSE Sep 19, 2025 15:31 PM
Volume: 959.0K
 

1119.20
-0.86%
ICICI Securities Limited
Natrol had annual sales of US$157 million (4.8% of consolidated sales) in FY20. Hence, this transaction values the business at 3.5x sales, a compelling deal by any standards. The company will utilise proceeds to reduce debt and other new strategic initiatives. We believe a significant portion of the company's current debt (| 4777 crore as of Q1FY21) is working capital based. Therefore, a major portion of cash generated through this deal is likely be utilised for strategic investments. The sale of this non-core segment is likely to improve focus on new and complex ventures such as biosimilars,...
Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0
More from Aurobindo Pharma Ltd.
Recommended